Introduction
The angiogenic factor, vascular endothelial growth factor (VEGF) and the two high-affinity tyrosine kinase receptors VEGF-1 (flt-1) and VEGFR-2 (KDR) have been well established as key regulators of physiologic endothelial cell growth and cell permeability in the process of normal angiogenesis. [1] [2] [3] [4] VEGF is produced and secreted by hematopoietic cells and is thus suggested as a pivotal factor in hematopoiesis, which specifically affects the differentiation of multiple hematopoietic lineages. 5 Recombinant human VEGF promotes the expansion of granulocyte-macrophage progenitors but inhibits the formation of erythroid bursts. Importantly, VEGF mediates human hematopoietic stem cell (HSC) survival and repopulation through an autocrine loop. 6 Expansion and invasion of leukemic cells are highly coordinated processes involving multiple growth factors and cytokines that are secreted by leukemic cells. Angiogenesis is important for leukemogenesis and chemosensitivity in AML. 6, 7 In human solid tumors, VEGF signalling plays an important role in tumor growth and metastatic dissemination. 8 The role of VEGF in hematopoietic malignancies has only recently been investigated. Expression of VEGF and its receptors is detected in the leukemic bone marrow and VEGF has been implicated as an essential mediator of leukemia-associated angiogenesis. 6 In addition, VEGF has been described as a potential autocrine or paracrine growth regulator in leukemia cells. 6 Expression of VEGF and VEGF receptors was first reported in chronic myelocytic leukemia (CML), and was then described in acute myeloid leukemia, childhood lymphoblastic leukemia and in myelodysplastic syndromes. [9] [10] [11] In CML, VEGF was detected at a high level in the bone marrow and peripheral blood. Moreover, VEGF expression was induced by the leukemic fusion protein BCR/ABL in CML cells. 12 Prolonged systematic administration of human recombinant VEGF in murine models results in intense medullary hyperplasia of immature myeloid elements and an arrest of erythroid maturation. 13 VEGF has also been shown to be an important growth, migration and survival factor in multiple myeloma cells. VEGF directly stimulates multiple myeloma cell migration on fibronectin through autocrine and paracrine loops. 14, 15 Further, VEGF receptor VEGFR-2 signalling plays a role in proliferation of leukemic cells. 16 Therapeutically targeting VEGF has benefited patients with advanced-stage solid tumors, in particular the metastatic colorectal cancer. 17 Members of the Cip/Kip family of cyclin-dependent kinase inhibitors are well characterized for their roles as negative regulators in the G 1 -phase cell cycle progression. 18 However, emerging studies suggest that p27 Kip1 play roles additional to cell cycle controls. P27
Kip1 protein levels are elevated in CML leukemic blasts. CML cells continue to proliferate despite the high level of p27 Kip1 . This may be due to that the majority of p27 Kip1 are located in the cell cytoplasm where they cannot bind to and inactivate the function of CDKs. 19 Several reported studies have linked p27
Kip1 to the regulation of actin dynamics and cell migration. 20 ,21 P27
Kip1
-deficient fibroblasts have decreased motility. Cytoplasmic p27
Kip1 could modulate actin dynamics by directly regulating the small Rac GTPase pathways. These studies suggested a role for p27 Kip1 in cell migration that might be independent of its role in cell cycle. The cytoplasmic role of p27
Kip1 in promoting cell migration may have an important role in carcinogenesis. 22 However, exactly how and through which pathway p27
Kip1 mediates the tumor cell migration remained unresolved.
A distinguishing feature of malignant cells is their capacity to invade surrounding normal tissues and migrate through the blood and lymphatic systems to distant organs. Metastatic tumors are thought to select for both invasive growth and cell migration. VEGF-mediated pathways and their effects on migration and invasiveness of leukemic cells still remain largely unknown. Further, the therapeutic benefit associated with VEGF-targeted therapy is complex, and probably involves multiple mechanisms, thus a better understanding of the mechanisms underlying VEGF action will lead to future advances in therapeutic interventions. This study aimed to evaluate the expression of VEGF and its clinical importance in patients with AML, as well as its functional consequences and cellular mechanisms related to leukemic cell growth, motility and drug resistance.
Materials and methods

Bone marrow samples and sections
Bone marrow samples from 10 healthy adults and 42 patients with AML were obtained as archival specimens from the Department of Pathology, Lund University, University Hospital in Malmö . The patient samples were obtained at the time of diagnosis and contained 90% leukemic blasts. For each case, all available hematoxylin-and eosin-stained sections were reviewed by a National Board certified pathologist and a representative block was selected for constructing tissue microarrays as described earlier 23 and were used for immunohistochemical analysis. The study was approved by the Ethics Committee at Lund University, and the Helsinki Declaration of Human Rights was strictly observed. The patient samples were divided into the AML subtypes M1 (n ¼ 24), M2 (n ¼ 10), M3 (n ¼ 6) and M5 (n ¼ 2) according to the French American and British classification system. Patients with subtype M1 and M2 underwent virtually the same treatment under a similar time period, in which cytotoxic drugs (a combination of Cytosar and Zavedos) were used, whereas all the M3 patients were treated with all-trans-retinoic acid for a similar period of time. A median follow-up of 5 years (range from 0.8 to 12 years) among the AML patients was applied in this study. Clinical characteristics of the patients have previously been described. 23 
Source of antibodies and plasmids
Antibodies used included: monoclonal antibodies specific for cyclin B1 (Upstate Biotech Inc., New York, NY, USA), cyclin A2, CDK1, CDK2 (Transduction Laboratory, San Jose, CA, USA), Ki-67 (Dako, Glostrup, Denmark), polyclonal antibodies against, VEGF, cyclin E, p27
Kip1 b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD34, CD15 and CD33 (DAKO Glostrup, Denmark), VEGF-neutralizing monoclonal antibody (MAB293), VEGF-receptor 2 blocking and IgG2b control antibodies (R&D systems, Abington, UK). VEGF-A (165) cDNA was obtained from human cDNA library and cloned into the eukaryotic expression plasmids pAAV-MSC (Stratagene, La Jolla, CA, USA) and the vector was designated as pMSC in this paper. Control flag vector and flag vector containing p27
Kip1 cDNA were kindly provided by Steven Balk (BIDMC, Harvard Medical School, Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA). pC2-EGFP contained Cyclin E cDNA and pC2-EGFP constructs used in this study, which were previously described. 24 
Immunohistochemistry
Deparaffinization of paraffin-embedded tissue samples (7 mm) was performed, and was followed by antigen retrieval in which slides were boiled in 0.01 M citrate buffer, pH 6.0, for 10 min. The staining procedure was performed using a semiautomatic staining machine (Ventana ES, Ventana Inc., Tucson, AZ, USA). The specimens were viewed with a Nikon 800 microscope and evaluated by four different specialists; one of them is a specialist on hemato-pathology. The staining intensity in normal bone marrow was scored as 1 (positive). The staining intensity in AML bone marrows was normalized by comparing the staining in normal bone marrows and was scored as 0 (negative), 1 (weakly positive or positive), 2 (strongly positive) and 3 (very strongly positive). For embedding cells from leukemic cell lines, cells were fixed in 4% paraformaldehyde, stained with Mayer's hematoxylin, then treated with 70% ethanol and incubated overnight before being embedded in paraffin and subsequently sectioned.
Immunofluorescence staining U937 cells were harvested, washed with PBS and cytospin (Cytospin2, Shandon, US) followed by fixation in 4% paraformaldehyde for 15 min at RT. After extensive washing in PBS, sections were permeabilized with 0.1% Triton X-100 for 5 min at RT. Sections were then washed in PBS and blocked in 1% BSA in PBS for 30 min. The sections were then incubated with primary antibodies for 1 h at RT, and were followed by the washing procedures. The incubation with secondary antibodies was carried out for 30 min. The fluorescence was viewed in Zeiss fluorescence microscope at magnification of Â 20.
Immunoblot analysis
For immunoblotting, cells were lysed in ice-cold RIPA lysis buffer (150 mM NaCl, 50 mM Tris-HCL pH 7.5, 1% NP-40, 10 mM NaF, 10 mM phenylmethylsulfonyl fluoride) and protease inhibitor cocktail Complete Mini (Roche, Basel, Switzerland) and centrifuged two times at 12 000 rpm for 30 min at 4 1C. The blotted membranes were probed with primary antibodies followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (Amersham Life Science, Alesbury, UK) and visualized using the enhanced chemi-luminescence detection system and films (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Cell culture, transfection and drug treatment
Human leukemic cell lines KG-1, HL-60 (myeloblasts), NB-4 (promyelocyte), U-937, THP-1 (monoblasts), K562 (erythroblast), DG-75 (lymphoblast) were maintained in RPMI-1640 medium (PAA Laboratories, Pashing, Austria) supplemented with 10% fetal calf serum (FCS) (Sigma, St Louis, MO, USA). Transient transfection was performed using an electroporation system with Nucleofection kit (AmaxaBiosystems, Cologne, Germany) according to the manufacturer's instruction. Plasmids (5 mg) were used for each transfection. For all-trans-retinoic acid (ATRA) treatment, cells were cultured in the medium containing ATRA (Sigma) dissolved in ethanol at a concentration of 10 mM for 24, 48 and 72 h. Control cells were treated with ethanol for the same time period. For induction of apoptosis, cells were treated with 20 mM camptothecin and harvested after 24 h. Apoptosis was analyzed by Annexin V-staining (BD Bioscences, Stockholm, Sweden) followed by flow cytometry analysis.
Cell proliferation assay
The effect of rh165 VEGF (Upstate Biotech, New York, NY, USA) on proliferation of U937 cells was determined after 48 h treatment using a non-radioactive BrdU incorporation-based cell proliferation assay kit (Roche, Switzerland) according to 
Apoptosis analysis
For cell cycle phase analysis, cells were washed in 1 Â PBS, resuspended in a solution containing 3.5 mM. Tris-HCl pH 7.6, 10 mM NaCl, 10 mg/ml propidium iodide, 20 mg/ml RNase and 0.1% v/v NP40 and then incubated in the dark for 20 min. Cells were then subjected to flow cytometry analysis using FACS Calibur (BD Biosciences, San Jose, CA, USA). Determination of apoptosis was based on the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) assay. To label the breaks in genomic DNA characteristic of apoptosis, cells were fixed and embedded in paraffin sections as described earlier. 25 TUNEL analysis was then performed by using ApoAlert DNA Fragmentation Assay Kit according to the manufacturer's instructions (Clontech, Palo Alto, CA, USA). Fluorescein-labeled cells were analyzed under a fluorescence microscope. Annexin V assay was performed following the manufacturer's instructions as described earlier. 25 
Motility and invasion assay
The migration/invasion of U-937 cells was measured by using Transwell chambers (Chemicon, Temecula, CA, USA) according to the manufacturer's protocol. Briefly, the cells were cultured in RPMI-1640 medium with or without VEGF (10 ng/ml) or neutralizing antibodies against VEGF (10 ng/ml) or VEGFR-2 (10 or 100 ng/ml). Cells were then seeded onto the membrane of the upper chamber of the transwell at a concentration of 3 Â 10 6 /ml in 500 ml medium. The RPMI-1640 medium containing 10% FBS was added to the lower chamber. Cells that passed through the Matrigel-coated membrane into the lower chamber were collected and counted or stained. The absorbance of the stained cells was measured on ELISA plate reader.
Statistical analysis
Statistical analyses were performed using SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). Spearman's correlation coefficient test was used to evaluate the strength of association between the continuous variables. The strength of association between the continuous variables is indicated with r s . The P-values used for comparison of variables between groups of patients were based on the Mann-Whitney U-test and the w 2 test or the student's t-test. Distributions of overall survival and disease-free survival were estimated by the method of Kaplan-Meier, with 95% confidence intervals. Differences between survival curves were calculated using the log-rank test. Statistical analyses were performed using SPSS version 10.1 (SPSS Inc., Chicago, IL, USA).
Results
Expression of VEGF protein in normal bone marrows
To determine the cell type-specific expression of VEGF protein in normal hematopoietic cells, immunohistochemical analysis was performed on tissue microarrays containing successfully preserved spots of bone marrow specimens from 10 healthy donors. To identify the myeloid lineage-specific expression of VEGF, the tissue microarrays were also simultaneously immunostained with antibodies against CD34 þ , CD15 or CD33, the cell surface markers specifically for hematopoietic progenitors and myeloid lineages. Expression of VEGF was detected in myeloid blasts, promyelocytes, myelocytes and megakaryocyte precursors, whereas mature granulocytic cells and erythroblasts were negative for VEGF expression (Table 1 ). These results suggest that VEGF is produced by the distinct cell types of early myeloid lineages.
Expression of VEGF in AML patients and clinical importance of VEGF expression in AML patients
Next, we examined VEGF expression in leukemic bone marrows from patients with AML. Cellular expression of VEGF was evaluated in bone marrow samples from 42 AML patients by immunohistochemical analysis. We compared the VEGF expression in the leukemic blasts with their normal hematopoetic counterparts from the 10 healthy bone marrows. VEGF expression was detected in 90% of the patients (Table 2) . Among the AML patients, 52% (22 out of the 42) patients had high levels of VEGF expression as compared with the normal bone marrows, and the remaining (48%) either lacked VEGF expression (n ¼ 4) or had expression (n ¼ 16) equal to the normal controls (Table 2) . VEGF expression was detected in cytoplasmic compartments of the leukemic cells (Figure 1a) .
To delineate whether VEGF expression correlates with disease characteristics and clinical outcome in patients with AML, we divided patients into two groups based on the level of VEGF expression: the VEGF-high (n ¼ 22) or VEGF-low group (n ¼ 20). We compared the differences between these two groups in relation to the clinical parameters including age, gender, leukocyte count, hemoglobin value, platelet value and cytogenetic abnormalities. Patients with high level of VEGF expression had statistically significant worse cytogenetics compared with patients with low levels of VEGF (P ¼ 0.02) ( Table 3 ). There Table 1 Expression of VEGF in normal myeloid cells
Cell type VEGF expression
Myeloblast + Promyelocyte + Myelocyte + Erythroblast À Megakarocyte precursor + Table 2 Expression of VEGF in subtypes of AML patients
The role of VEGF B Wegiel et al were no statistically significant differences in age, gender, leukocyte count, hemoglobin value and platelet counts between VEGF low and VEGF-high groups. To investigate whether VEGF expression may have clinical importance and predict patient outcome in this patient cohort, we analyzed overall survival and disease-free survival using Kaplan-Meier analysis. Analysis of overall survival with a median follow-up of 66 months ranging from 1 to 132 months showed that complete remission (CR) rate appeared to be lower in VEGF-high group compared with VEGF-low group (Figure 2a) . The CR rate of 31.3% in the VEGFhigh group compared with 42.3% in the VEGF-low group (P ¼ 0.30). However, there was no significant difference in disease-free survival between the two groups ( Figure 2b ). This result suggests that patients with high level of VEGF appeared to have lower remission rate compared with patients with lower VEGF, although this was not statistically significant, probably owing to the small number of patients.
Correlation between VEGF and p27 Kip1 as well as the other cell cycle regulators in AML patients
To investigate whether there is a link between VEGF expression and proliferation of leukemic cells, the percentage of Ki-67-positive cells was measured in the bone marrows of these patients. Correlation between the level of VEGF expression and Ki-67 was further evaluated. Spearman's correlation test revealed that there was a statistically significant correlation between the level of VEGF expression and Ki-67-positive cells (r 2 s ¼ 0.378, P ¼ 0.013) suggesting that VEGF expression is positively related to the rate of proliferation in leukemic cells. We then asked whether the expression of VEGF might correlate to the major cell cycle proteins controlling G 1 /S and G 2 /M phases of cell cycle. Spearman's correlation assay showed that VEGF expression statistically significantly correlated with the expression of cyclin A1, cyclin A2, cyclin B1, cyclin E and CDK2 (Table 4) . As p27
Kip1 has been shown to be highly expressed in the cytoplasmic compartments of leukemic cells in CML patients 19 and the expression of p27 Kip1 contributes to migration in cell lines derived from solid tumors, 22 we investigated whether there was a correlation between VEGF and p27 Kip1 . Expression of VEGF is statistically significantly correlated with p27
Kip1 (P ¼ 0.001) ( Table 4) . To investigate whether p27
Kip1 expression may be associated with patient outcome, Kaplan-Meier analysis was performed. Expression of p27
Kip1 was used to stratify the patients into p27 Kip1 -positive group and p27 Kip1 -negative group. There were no statistically significant differences between p27 Kip1 -positive and p27 Kip1 negative group in overall survival and disease-free survival (Figures 2c and d) . Next, we examined whether VEGF and P27
Kip1 expression have additive impact on patient outcome. We divided patients into two groups: the VEGF-high and 
Cytogenetic data
Abbreviation: CR, complete remission after initial therapy. The role of VEGF B Wegiel et al p27 Kip1 -positive group and the VEGF-low and p27 Kip1 -negative group. Interestingly, patients with high VEGF levels and were p27 Kip1 -positive had much lower CR (28.6%) compared with patients with low VEGF levels and were p27
Kip1 -negative (37.5%), although it did not achieve the statistical significance (P ¼ 0.840). This result indicates that VEGF and p27
Kip1 in combination may have potential impact on patient outcome and such study need to be applied in large numbers of patients in the future studies.
Expression of VEGF in leukemic cell lines
To examine the expression of VEGF in leukemic cell lines, cell line micro-array was constructed in which a panel of human leukemic cell lines from myeloid and lymphoid lineages including KG1, HL-60, NB-4, THP-1, U-937, K-562 and DG-75 cells were fixed in formalin and paraffin-embedded on the same block. Immunohistochemical analysis was performed on the cell line array using an antibody against VEGF. The overall level of VEGF expression in myeloid and lymphoid cell lines Stimulation of U-937 cells with VEGF recombinant protein resulted in an increase in cell proliferation rate
Because VEGF expression statistically significantly correlated with the expression of the cell cycle regulatory proteins in AML patients, we wanted to investigate whether VEGF expression may affect cellular proliferation and the expression of these cell cycle regulators in U-937 cells. U-937 cells were cultured in serum-free medium for 48 h before the addition of the recombinant human r165VEGF at doses from 0.1 ng/ml up to 10 ng/ml. The effect of exogenous VEGF on cellular proliferation in U-937 cells after 48-h of VEGF stimulation was analyzed by BrdU incorporation assay. Treatment of U-937 cells with rVEGF165 at concentrations of 0.1, 1 and 10 ng/ml greatly increased the proliferation rate in U-937 cells (Figure 3a) . Immunoblot analysis was performed to evaluate the effect of exogenous VEGF (10 ng/ml) on the expression of cyclin A2, cyclin B1, CDK1, CDK2 and p27 (Figure 3b ). The level of cyclin A2 was higher in U-937 cells cultured in the medium containing r165VEGF than that in U-937 cells cultured in serum-free medium. Interestingly, there was also a significant increase in p27 Kip1 in U-937 cells treated with r165VEGF compared with that in control cells. This suggests that exogenous VEGF has a predominant effect on the expression levels of cyclin A2 and p27
Kip1 in U-937 cells.
Inhibition of proliferation by blocking of autocrine VEGF signalling
As addition of VEGF led to the increased proliferation rate in U-937 cells, we wanted to investigate whether this effect was mediated by VEGF autocrine pathways. The effects of VEGF were blocked in two ways: by neutralizing secreted VEGF with anti-VEGF mAb or by inhibiting VEGF receptor signalling. U-937 cells were firstly treated with 1 ng/ml VEGF for 48 h, the control isotype antibody IgG2b at 50 ng/ml or VEGF-neutralizing antibodies at 10 or 50 ng/ml were then added into the culture medium. The effect of VEGF-neutralizing antibodies on proliferation in U-937 cells treated with exogenous VEGF was assessed by BrDU incorporation-based assay. As shown in Figure 4a , cellular proliferation stimulated by VEGF was not altered when control antibody IgG2b was added together with r165VEGF into U937 cells. However, anti-VEGF mAb at 10 and 50 ng/ml sufficiently inhibited VEGF-stimulated proliferation by 35% (Figure 4a ). This result indicates that the VEGF-dependent pathways stimulated cell growth can be blocked by neutralization of secreted VEGF. Next, we investigated whether VEGF receptor signalling may also have effect on U-937 cell growth. Treatment of U-937 cells with the anti-VEGFR-2 mAb at 10 or 100 ng/ml inhibited VEGF-induced proliferation rate in U-937 cells (Figure 4b ). Anti-VEGFR-2 mAb at 100 ng/ml significantly blocked the effect of exogenous VEGF, although this inhibitory effect was less sufficient compared to the blocking effect of neutralization of VEGF. These results suggest that VEGF/VEGFR2 signalling affects the proliferation in U-937 cells.
Overexpression of VEGF in U-937 cells promoted survival of U-937 cells to therapeutic agents-induced apoptosis
We then investigated whether VEGF expression plays a role in the survival response of leukemic cells to the therapeutic agents. We overexpressed VEGF by transiently transfected U-937 cells with VEGF-pMCS expression vector or control pMCS vector. Figure 5a ). We then determined whether VEGF is involved in the survival of U-937 cells in response to ATRA treatment. U-937 cells overexpressing VEGF or control vector were treated with 10 mM ATRA for 72 h and the apoptotic rates were determined by TUNEL assay. The proportion of TUNEL-positive cells was similar in U-937 cells overexpressing VEGF and in cells expressing control vector (Figure 5b) . However, the rate of ATRA-induced apoptotic cells was significantly reduced in U-937 cells overexpressing VEGF (21 ± 2%) compared with that in control cells (42 ± 3%) (Figure 5b ). This result suggests that VEGF expression is involved in the survival effect of U-937 cells in response to ATRA treatment. Next, we examined whether VEGF expression is involved in the response of U-937 cells to the cytotoxic agent, and camptothecin-induced apoptosis. U937 cells overexpressing VEGF or control vector were treated with 20 mM camptothecin for 24 h, and the rate of apoptosis was assessed by Annexin V-staining followed by flow cytometry analysis. As shown in Figure 5c , camptothecin-induced apoptosis in U-937 cells overexpressing VEGF was only 50% of the rate of the U-937 cells expressing control vector. This suggests that VEGF reduced the sensitivity of the leukemic cells to ATRA or camptothecin-induced apoptosis, thus allowed the cells to gain the survival advantages.
Effect of VEGF production on U-937 cell migration/ invasion
Cell migration and invasion plays a key role in tumor metastasis and drug resistance. We investigated the influence of the autocrine VEGF signalling on U-937 cell migration. U-937 cells were treated with human r165VEGF at 10 ng/ml for 72 h, and the effect of exogenous VEGF expression on the motility of U-937 cells was assessed using Matrigel-coated Boyden invasion chambers. A higher proportion of U-937 cells that had been stimulated by exogenous r165VEGF passed through a Matrigelcoated membrane, compared with cells that had not been treated with r165VEGF ( Figure 6a ). To investigate whether the effect of VEGF expression on cell migration was mediated by autocrine pathways, we inhibited VEGF expression by adding anti-VEGF mAb at 50 ng/ml into U-937 cells that have already been treated with r165VEGF. The rate of migration of U-937 cells due to secreted endogenous VEGF was partially abrogated when the cells were treated with anti-VEGF mAb (Figure 6a ). The control antibody IgG did not have any inhibitory effect on VEGF-induced migration. We then investigated whether VEGF receptor autocrine pathways play a role in the motility of U-937 cells. Blockage of VEGF signalling by adding the anti-VEGFR-2 mAb to U-937 cells also inhibited the VEGF-induced migration of U-937 cells (Figure 6b ). These results suggest that the invasion of U-937 cells is mediated by VEGF and VEGFR2 autocrine signalling.
p27 Kip1 is involved in VEGF-induced invasion of U-937
The cellular mechanisms by which VEGF signalling promotes migration and invasion in leukemic cells still remain unknown. Because we found that VEGF expression positively correlated with p27 expression in AML patients, and recently reported studies showed that p27 Kip1 expression modulated cellular migration, 21, 26 we therefore investigated whether p27 Kip1 contributes to VEGF-mediated receptor signalling and their effects on proliferation and migration in U-937 cells. We overexpressed p27 Kip1 by transiently transfected U-937 cells with p27
Kip1 expressing vector or control vector (Figure 7a ). We then investigated whether overexpression of p27
Kip1 has any effect on VEGF production or VEGF receptor expression by ELISA assay and western blot analysis. There were no changes in VEGF and VEGFR2 expression in U-937 cells overexpressing p27
Kip1 compared with cells expressing control vector (data not shown), suggesting that p27
Kip1 is not the primary regulator of VEGF and VEGFR2. Next, we investigated whether p27
Kip1 may contribute to an additive effect on VEGF-mediated receptor signaling. We co-overexpressed VEGF and p27
Kip1 by transiently co-transfected U-937 cells with plasmids containing VEGF and p27 Kip1 . As VEGFR2 is a mediator of VEGF effects on cell proliferation and migration, we therefore examined the effect of 
co-expression of VEGF and p27
Kip1 on the expression and subcellular localization of VEGFR2 by immunofluorescence staining of the cells using antibody against FITC-conjugated antibody against VEGFR-2. The sites of VEGFR2 expression in U-937 cells appeared to be both cytosolic and membrane (Figure 7b) . Interestingly, the cytosolic and membrane signals of VEGFR2 were greatly enhanced in U-937 cells co-overexpressing VEGF and p27 Kip1 (Figure 7b ). Next, we examined whether there are additive effects of VEGF and p27
Kip1 expression on U-937 cell growth. BrdU-based proliferation assay was performed on various U-937 transfectants. Proliferation rate was similar in U-937 cells overexpressing VEGF alone and in cells co-expressing VEGF and p27 Kip1 , suggesting that p27
Kip1 had no additive effect on VEGF-induced proliferation (Figure 7c ). To further examine the effect of coexpression of VEGF and p27 on U-937 cell migration and invasion, invasion assay was conducted. U-937 cells transfected with p27
Kip1 displayed a similar migratory rate compared with U-937 cells transfected with control vector (data not shown). Interestingly, U-937 cells co-expressing VEGF and p27
Kip1 had a significantly higher migration/invasion rate compared with cells expressing VEGF alone, suggesting that p27
Kip1 greatly enhanced VEGF-induced migratory ability in U-937 cells (Figure 7d ). Taken together, these results suggest that p27 Kip1 co-operates with VEGF to mediate VEGFR2 receptor signaling and to regulate migration and invasion in U-937 cells.
Discussion
Hematopoietic progenitors and terminally differentiated precursor cells produce and secrete multiple growth factors, including VEGF and EGF, which promote differentiation of hematopoietic cells. 4 However, little is known about the role of VEGF and VEGF-mediated signalling pathways in the regulation of growth, differentiation and survival of hematopoietic cells. Recently, VEGF and its receptors have been considered as the important components that contribute to the pathogenesis of hematological malignancies. 6 The aim of our present study was therefore to: (i) evaluate the possible association between VEGF and clinical features; (ii) investigate the clinical impact of VEGF in combination with other key regulators, in particular, p27
Kip1 in AML patients; iii. investigate the role of VEGF and its associated novel pathways in the regulation of growth, survival and migration/invasion of leukemic cells. In this study, we observed that VEGF was expressed in early myeloid lineages including myeloblasts, promyelocytes, myelocytes and megakaryocytes, whereas it The role of VEGF B Wegiel et al was absent in erythroid cells. Our data provided evidence on that VEGF protein is expressed in the majority of the myeloid cell types, which reflects a pivotal role for this angiogenic factor in the differentiation of multiple hematopoietic lineages. This is in consistence with the reported studies in which VEGF is suggested to control the basic mechanisms of proliferation and differentiation in hematopoietic stem and progenitor cells. 27 VEGF is a critical angiogenic factor that is crucial to disease progression and metastases in solid tumors, 28 and it has been suggested to act as a mediator of disease-associated angiogenesis in patients with myeloid leukemia. 29, 30 However, only a few reported studies have shown that VEGF has a prognostic role in predicting patient outcome in leukemia 31 In this study, we have shown that VEGF is highly expressed in 52% of AML patients. VEGF expression is associated with several clinical features. Patients with high level of VEGF expression had statistically significant worse cytogenetics compared with patients with low levels of VEGF (P ¼ 0.02). There was a clear trend that patients with higher VEGF expression had worse disease-free survival. In addition, patients with high level of VEGF expression appeared to have lower CR rates compared to those with lower expression, although this did not achieve a statistical significance, probably owing to the lower patient numbers. Our results provide novel evidence, which suggests that VEGF expression is linked to several important clinical features and its expression is also related to the treatment responsiveness in AML patients.
Several redundant pathways are responsible for growth and invasion of the cancer cells. To develop innovative therapeutic strategies for treating malignancies, it is important to know about the pathways and interactions between and among different molecules in malignant cells. In this study, we delineated co-factors that mediated the VEGF effects on The role of VEGF B Wegiel et al leukemic cell migration and invasion. We showed that there was an interplay between VEGF and p27 Kip1 in leukemic patients and U-937 leukemic cells. In AML patients, we found that there was a statistically significant correlation between the expression of VEGF and p27
Kip1 in AML patients. Patients with high VEGF levels and were p27
Kip1 positive had lower rate to achieve the CR compared with patients with low VEGF levels and were p27
Kip1 negative. This result suggests that patients who co-express high level of VEGF and p27
Kip1 may be less responsive to the treatment compared with those with low levels. It has been reported that p27
Kip1 has a cell cycle independent role, and its expression modulated cellular migration. 21, 26 By using U-937 cell line system, we demonstrated that there was an additive effect of combining both VEGF and p27
Kip1 expression on leukemic cell migration and invasion. We further showed that VEGFR-2 cytoplasmic and membrane accumulation was significantly enhanced by co-expressing p27 Kip1 and VEGF in U-937 cells. Such a phenotype may be related to the invasive potential of leukemic cells. Our results suggest that p27
Kip1 may interact or regulate either receptor expression or VEGFR2-signalling pathways and enhance the effects of VEGF autocrine loop on leukemic cells.
The mechanisms of drug resistance in leukemic cells are poorly understood. A major challenge for leukemic cell-targeted therapy is to identify the molecular pathways that mediate treatment resistance. In this study, we studied the effect of VEGF expression on the treatment response of U-937 cells to ATRA or campthotecin. We showed that ATRA or campthotecin effectively induced apoptosis in control U-937 cells. However, either ATRA or campthotecin treatment induced significantly less cell death in U-937 cells overexpressing VEGF. These findings suggest that cells overexpressing VEGF were less sensitive to chemotherapeutic agents. VEGF may mediate the leukemic cells to escape the cell death induced by the chemotherapeutic agents. Thus, leukemic cells with high level of VEGF may be more resistant to the treatment. It has also been shown that VEGF induces the expression of heat-shock protein hsp90 and its binding to Bcl-2 thereby increasing leukemic cells resistance to serum deprivation-induced apoptosis. 16, 32 Because VEGF promotes neovascularisation and interacts with MMPs to promote tumor metastasis in solid tumors, it is an urgent need to study whether the effects of VEGF on the neovasulature in the leukemic bone marrow plays a role in malignant progression and treatment resistance.
Very little is known about the role of VEGF and VEGFmediated signalling pathways in the regulation of cell growth and migration of leukemic cells. It has previously been shown that VEGF signalling is involved in the process of cell growth. Inhibition of VEGF receptors reduces angiogenic activity and appears to either directly or indirectly inhibit the growth of leukemic cells. 33, 34 In this study, we demonstrated that the rate of cellular proliferation was significantly increased in U-937 cells stimulated by autocrine VEGF. Our results suggest that VEGF has the ability to influence cellular pathways in cell proliferation and cell cycle. We further showed that the effect of VEGF on cellular proliferation was blocked by both VEGF neutralizing antibody and by VEGFR2 inhibitor. This suggests that the action of autocrine VEGF/VEGFR2 loops on leukemic cells was mediated by both the external VEGF and the internal VEGF receptors. The interaction of VEGF with VEGFR2 appeared to be important for the proliferation of leukemic cells. Our results are consistent with the reported studies in which VEGF-VEGFR-2 pathways play an important role in the regulation of cell growth and migration in leukemic cells. This also suggests that blocking the VEGF/VEGFR-2 pathways may be essential to achieve clinical remission in a subset of AML.
In addition, we have demonstrated for the first time that VEGF is able to promote invasion of U-937 cells. Blocking the VEGF and VEGFR2 with the inhibitors significantly reduced the ability of U-937 cells to invade through the reconstituted basement membrane. Interestingly, the internal VEGFR2 inhibitor is more effective at reducing the invasion than the external VEGF blocker. These results may have fundamental clinical relevance, when trying to target secreted VEGF or internal VEGF receptor 2 Kip1 -flag vector and VEGF-pMCS vector together. The rate of invasion and migration was measured in these cells by invasion assay. Pp0.05 was indicated as one asterisk. Data presented are average of three independent experiments, each conducted in duplicates ( ± s.d.).
for therapeutic purposes. Study the role of VEGF in leukemogenesis and leukemic cell survival, invasion and proliferation is of importance for the full understanding of diseases and for the implementation of disease-specific drug design. Our results suggest that VEGF and VEGF-associated pathways will provide intriguing insights into the nature of hematological malignancy and treatment interventions.
